LCM
ALXO icon

Legato Capital Management’s ALX Oncology ALXO Stock Holding History

Legato Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,697
Closed -$366K – 197
2021
Q2 		$366K Buy
+6,697
New +$401K 0.05% 292

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Legato Capital Management's ALXO Position: Q3 2021 in Review

Legato Capital Management sold out of ALX Oncology (ALXO) in Q3 2021, closing a stake of 6,697 shares — an estimated $366K sold.

Legato Capital Management first reported a position in ALXO in Q2 2021 and held it in 1 quarter. The position peaked at $366K in Q2 2021. 114 funds tracked by Wall St. Rank hold ALXO as of Q3 2021.

  • Legato Capital Management reported no remaining ALX Oncology position as of Q3 2021 after selling out during the quarter.
  • Legato Capital Management sold 6,697 ALX Oncology shares in Q3 2021, an estimated $366K.
  • Legato Capital Management first reported a position in ALX Oncology in Q2 2021 and held it in 1 quarter.
  • Legato Capital Management's ALX Oncology position peaked at $366K in Q2 2021.
  • 114 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2021.

Based on Legato Capital Management's 13F filing for Q3 2021, filed 9 Nov 2021.